title: Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.
abstract: BACKGROUND
  Effective management of major depressive disorder often includes the long-term use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole has not been evaluated in a controlled setting.
  
  
  METHODS
  Patients (n = 706) completing one of two 14-week double-blind studies of aripiprazole augmentation, as well as de novo patients (n = 296) nonresponsive to current antidepressant therapy, were enrolled in this open-label study. Patients received open-label aripiprazole for up to 52 weeks.
  
  
  RESULTS
  Open-label treatment was completed by 323 patients (32.2%). At endpoint (n = 987), the mean dose of aripiprazole was 10.1 mg/day. Common (>15% of patients) spontaneously reported adverse events were akathisia (26.2%), fatigue (18.0%), and weight gain (17.1%). The incidence of serious adverse events was 4.0%. Four spontaneous reports of possible tardive dyskinesia were submitted (0.4%); all resolved within 45 days of drug discontinuation. Mean weight change was 4.4 kg; 36.6% experienced ≥7% increase in weight from baseline (observed case analysis, n = 303). No clinically relevant changes in other metabolic parameters were seen. At the end of open-label treatment, 221 patients (69.7%) had a Clinical Global Impression-Severity of Illness score of 1 (not at all ill) or 2 (borderline ill).
  
  
  CONCLUSIONS
  Long-term adjunctive aripiprazole therapy was well tolerated with an acceptable long-term safety and tolerability profile in patients with major depressive disorder who had not responded to treatment with one or more antidepressant therapies. Clinically significant weight gain was observed in about one-third of patients. Overall, the adverse event profile was consistent with that reported in the short-term trials and readily managed clinically.
authors.affiliation: Neuroscience Global Clinical Research Bristol-Myers Squibb, Wallingford, CT, USA;
authors.forename: Robert M
authors.initials: RM
authors.lastname: Berman
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
authors.forename: Madhukar H
authors.initials: MH
authors.lastname: Trivedi
authors.forename: James A
authors.initials: JA
authors.lastname: Hazel
authors.forename: Sabrina Vogel
authors.initials: SV
authors.lastname: Marler
authors.forename: Robert D
authors.initials: RD
authors.lastname: McQuade
authors.forename: William
authors.initials: W
authors.lastname: Carson
authors.forename: Ross A
authors.initials: RA
authors.lastname: Baker
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Marcus